A chimeric receptor that selectively targets membrane-bound carcinoembryonic antigen (mCEA) in the presence of soluble CEA

被引:83
作者
Hombach, A
Koch, D
Sircar, R
Heuser, C
Diehl, V
Kruis, W
Pohl, C
Abken, H
机构
[1] Univ Cologne, Innere Med Klin 1, Lab Tumor Genet, D-50924 Cologne, Germany
[2] Evangel Krankenhaus Koln Kalk, Cologne, Germany
关键词
chimeric T cell receptor; scFv; membrane-bound CEA;
D O I
10.1038/sj.gt.3300813
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Chimeric T cell receptors with specificity for tumor-associated antigens are successfully used to target T cells to tumor cells. The efficacy of this approach, however, is reduced by soluble antigen that is frequently present in high serum concentrations. To overcome this situation, we constructed an anti-CEA chimeric receptor whose extracellular moiety is composed of a humanized single chain antibody fragment (scFv) derived from the anti-CEA mAb BW431/26 and the CH2/CH3 constant domains of human IgG. The intracellular moiety consists of the gamma-signaling chain of the human Fc epsilon RI receptor constituting a completely humanized chimeric receptor. After transfection, the humBW431/26 scFv-CH2CH3-gamma receptor is expressed as a homodimer on the surface of MD45 T cells. Go-incubation with CEA(+) tumor cells specifically activates grafted MD45 T cells indicated by IL-2 secretion and cytolytic activity against CEA(+) tumor cells. Notably, the efficacy of receptor-mediated activation is not affected by soluble CEA up to 25 mu g/ml demonstrating the usefulness of this chimeric receptor for specific cellular activation by membrane-bound CEA even in the presence of high concentrations of CEA, as found in patients during progression of the disease.
引用
收藏
页码:300 / 304
页数:5
相关论文
共 18 条
  • [1] Can combined T-cell- and antibody-based immunotherapy outsmart tumor cells?
    Abken, H
    Hombach, A
    Reinhold, U
    Ferrone, S
    [J]. IMMUNOLOGY TODAY, 1998, 19 (01): : 2 - 5
  • [2] FLUORESCENT EUROPIUM CHELATES AS TARGET-CELL MARKERS IN THE ASSESSMENT OF NATURAL-KILLER-CELL CYTOTOXICITY
    BLOMBERG, K
    ULFSTEDT, AC
    [J]. JOURNAL OF IMMUNOLOGICAL METHODS, 1993, 160 (01) : 27 - 34
  • [3] IMMUNOHISTOCHEMICAL LOCALIZATION AND MOLECULAR CHARACTERISTICS OF 3 MONOCLONAL ANTIBODY-DEFINED EPITOPES DETECTABLE ON CARCINOEMBRYONIC ANTIGEN (CEA)
    BOSSLET, K
    LUBEN, G
    SCHWARZ, A
    HUNDT, E
    HARTHUS, HP
    SEILER, FR
    MUHRER, C
    KLOPPEL, G
    KAYSER, K
    SEDLACEK, HH
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1985, 36 (01) : 75 - 84
  • [4] CHARACTERIZATION OF A HUMANIZED BISPECIFIC MONOCLONAL-ANTIBODY FOR CANCER-THERAPY
    BRUYNCK, A
    SEEMANN, G
    BOSSLET, K
    [J]. BRITISH JOURNAL OF CANCER, 1993, 67 (03) : 436 - 440
  • [5] The T-body approach: Potential for cancer immunotherapy
    Eshhar, Z
    Bach, N
    FitzerAttas, CJ
    Gross, G
    Lustgarten, J
    Waks, T
    Schindler, DG
    [J]. SPRINGER SEMINARS IN IMMUNOPATHOLOGY, 1996, 18 (02): : 199 - 209
  • [6] SPECIFIC ACTIVATION AND TARGETING OF CYTOTOXIC LYMPHOCYTES THROUGH CHIMERIC SINGLE CHAINS CONSISTING OF ANTIBODY-BINDING DOMAINS AND THE GAMMA-SUBUNIT OR ZETA-SUBUNIT OF THE IMMUNOGLOBULIN AND T-CELL RECEPTORS
    ESHHAR, Z
    WAKS, T
    GROSS, G
    SCHINDLER, DG
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (02) : 720 - 724
  • [7] CARCINOEMBRYONIC ANTIGEN
    FLETCHER, RH
    [J]. ANNALS OF INTERNAL MEDICINE, 1986, 104 (01) : 66 - 73
  • [8] Chimaeric T-cell receptors specific to a B-lymphoma idiotype: A model for tumour immunotherapy
    Gross, G
    Levy, S
    Levy, R
    Waks, T
    Eshhar, Z
    [J]. BIOCHEMICAL SOCIETY TRANSACTIONS, 1995, 23 (04) : 1079 - 1082
  • [9] ENDOWING T-CELLS WITH ANTIBODY SPECIFICITY USING CHIMERIC T-CELL RECEPTORS
    GROSS, G
    ESHHAR, Z
    [J]. FASEB JOURNAL, 1992, 6 (15) : 3370 - 3378
  • [10] HWU P, 1995, CANCER RES, V55, P3369